Funding Challenges in European Biotech: The Disparity and Its Implications

In this week's podcast,

 is joined by

at

and

at

to explore one of the most consequential deep tech opportunities Europe faces: RNA. With roots in foundational biology and applications from cancer therapy to precision agriculture, RNA is both a symbol and a stress test of Europe’s capacity to scale science into sovereignty.

The conversation is based on their

on the State of RNA in Europe, a data-rich, in-depth analysis of patents, funding flows, regulatory bottlenecks, and startup activity across the continent.

Here’s what’s covered:

• 03:05 The State of RNA in Europe
• 05:59 Challenges in Commercialization and Investment
• 09:09 The Landscape of RNA Companies in Europe
• 15:02 Regulatory Challenges in RNA Development
• 17:58 The Future of RNA in Europe
• 26:54 Navigating Regulatory Challenges in Biocontrol Products
• 30:46 The Impact of European Policies on Innovation
• 32:41 Learning from Global Regulatory Practices
• 40:34 The Exodus of Talent and Innovation from Europe
• 45:59 Funding Challenges for RNA Companies in Europe